Recovering the osteoblastic differentiation potential of mesenchymal stem cells derived from diabetic rats by photobiomodulation therapy.
Natália Pieretti BuenoIsabella Nunes CopeteHelena Bacha LopesPraveen R AranyMárcia Martins MarquesEmanuela Prado FerrazPublished in: Journal of biophotonics (2020)
Autologous cell-based therapy for bone regeneration might be impaired by diabetes mellitus (DM) due to the negative effects on mesenchymal stem cells (MSCs) differentiation. Strategies to recover their osteogenic potential could optimize the results. We aimed to evaluate the effect of photobiomodulation (PBM) therapy on osteoblast differentiation of rats with induced DM. Bone marrow MSCs of healthy and diabetic rats were isolated and differentiated into osteoblasts (OB and dOB, respectively). dOB were treated with PBM therapy every 72 hour (660 nm; 0.14 J; 20 mW; 0.714 W/cm2 , and 5 J/cm2 ). Cell morphology, viability, gene and protein expression of osteoblastic markers, alkaline phosphatase (ALP) activity, and the mineralized matrix production of dOB-PBM were compared to dOB. PBM therapy improved viability of dOB, increased the gene and protein expression of bone markers, the ALP activity and the mineralized matrix production. PBM therapy represents an innovative therapeutic approach to optimize the treatment of bone defects in diabetic patients.
Keyphrases
- mesenchymal stem cells
- diabetic rats
- bone marrow
- bone regeneration
- cell therapy
- umbilical cord
- oxidative stress
- single cell
- type diabetes
- gene expression
- genome wide
- dna methylation
- photodynamic therapy
- blood pressure
- transcription factor
- insulin resistance
- copy number
- drug induced
- metabolic syndrome
- risk assessment
- endothelial cells
- vascular smooth muscle cells
- human health
- newly diagnosed
- genome wide analysis